| Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial J Rosenstock, C Wysham, JP Frías, S Kaneko, CJ Lee, LF Landó, H Mao, ... The Lancet 398 (10295), 143-155, 2021 | 621 | 2021 |
| Comprehensive characterization of molecular differences in cancer between male and female patients Y Yuan, L Liu, H Chen, Y Wang, Y Xu, H Mao, J Li, GB Mills, Y Shu, L Li, ... Cancer cell 29 (5), 711-722, 2016 | 290 | 2016 |
| Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial WT Garvey, JP Frias, AM Jastreboff, CW le Roux, N Sattar, D Aizenberg, ... The Lancet 402 (10402), 613-626, 2023 | 142 | 2023 |
| Propensity score weighting analysis and treatment effect discovery H Mao, L Li, T Greene Statistical methods in medical research 28 (8), 2439-2454, 2019 | 98 | 2019 |
| Structural and molecular basis for coordination in a viral DNA packaging motor H Mao, M Saha, E Reyes-Aldrete, MB Sherman, M Woodson, R Atz, ... Cell reports 14 (8), 2017-2029, 2016 | 73 | 2016 |
| On the propensity score weighting analysis with survival outcome: Estimands, estimation, and inference H Mao, L Li, W Yang, Y Shen Statistics in medicine 37 (26), 3745-3763, 2018 | 53 | 2018 |
| Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer HA Yu, LG Paz-Ares, JCH Yang, KH Lee, P Garrido, K Park, JH Kim, ... Clinical Cancer Research 27 (4), 992-1002, 2021 | 40 | 2021 |
| SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo … WT Garvey, JP Frias, AM Jastreboff, CW Le Roux, N Sattar, D Aizenberg, ... Lancet 402 (10402), 613-626, 2023 | 24 | 2023 |
| Flexible regression approach to propensity score analysis and its relationship with matching and weighting H Mao, L Li Statistics in medicine 39 (15), 2017-2034, 2020 | 19 | 2020 |
| Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1) CJ Lee, H Mao, VT Thieu, LF Landó, MK Thomas Journal of the Endocrine Society 7 (5), bvad056, 2023 | 14 | 2023 |
| NMR structure of a vestigial nuclease provides insight into the evolution of functional transitions in viral dsDNA packaging motors BP Mahler, PJ Bujalowski, H Mao, EA Dill, PJ Jardine, KH Choi, ... Nucleic acids research 48 (20), 11737-11749, 2020 | 14 | 2020 |
| PSW: Propensity score weighting methods for dichotomous treatments H Mao, L Li R package version, 1.1-3, 2018 | 10 | 2018 |
| Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma … A Necchi, H Nishiyama, N Matsubara, JL Lee, DP Petrylak, R de Wit, ... BMC urology 20, 1-11, 2020 | 6 | 2020 |
| Phase I study of ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, preliminary efficacy, and pharmacokinetic findings M Saleh, PA Cassier, L Eberst, G Naik, VK Morris, S Pant, C Terret, L Gao, ... The Oncologist 25 (11), e1628-e1639, 2020 | 6 | 2020 |
| CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-positive EGFR-Mutant NSCLC YH Paz-Ares L, Planchard D, Yang J, Lee KH, Lopez PG, Park K, Kim JH, Lee DH ... Journal of Thoracic Oncology 13 (10), S453-S454, 2018 | 4 | 2018 |
| Estimating the prevalence of atrial fibrillation from a three-class mixture model for repeated diagnoses Li L, Mao H, Ishwaran H, Rajeswaran J, Ehrlinger J, Blackstone EH Biometrical Journal 59 (2), 331-343, 2016 | 4* | 2016 |
| Effects of tirzepatide on 24-hour ambulatory blood pressure and heart rate in adults with obesity-results from the SURMOUNT-1 ambulatory blood pressure monitoring sub-study JA De Lemos, CW Le Roux, H Mao, NN Ahmad, S Zhang, M Bunck, ... Circulation 146 (Suppl_1), A10370-A10370, 2022 | 3 | 2022 |
| Weekly dual GIP/GLP-1 receptor agonist tirzepatide monotherapy improved markers of islet cell function and insulin sensitivity in people with type 2 diabetes (SURPASS-1) CJ Lee, VT Thieu, H Mao, MK Thomas Diabetologia 64 (SUPPL 1), 245-246, 2021 | 3 | 2021 |
| Tirzepatide-induced weight loss is associated with body composition improvements across age groups R Kushner, L Aronne, A Stefanski, N Ahmad, H Mao, M Bunck, ... Obesity 30, 49-49, 2022 | 2 | 2022 |
| Efficacy and Safety of Once Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist Versus Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1) J Rosenstock, C Wysham, JP Frias, S Kaneko, CJ Lee, LF Landó, H Mao, ... Diabetologie und Stoffwechsel 17 (S 01), P 028, 2022 | 1 | 2022 |
